8-K 1 a8-kscientificresultxg.htm 8-K SCIENTIFIC RESULT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 21, 2019

Dyadic International, Inc.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) | 000-55264 (Commission File Number) | 45-0486747 (I.R.S. Employer Identification Number)
140 Intracoastal Pointe Drive, Suite 404 Jupiter, FL 33477 |  |
(Address of principal executive offices and zip code) |  |
(561) 743-8333 |  |
(Registrant’s telephone number, including area code) |  |
N/A (Former Name or Former Address, if Changed Since Last Report) |  |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | DYAI | The NASDAQ Stock Market LLC

Item 8.01 Other Events
On November 25, 2019, Dyadic International, Inc. (the “Company”) announced that data presented at the annual PEGS Europe Protein & Antibody Engineering Summit demonstrated that its C1 strain has been successfully glyco-engineered to impart the core human like G0 glycan structure at high levels.
The G0 glycosylation data was presented by Markku Saloheimo, Ph.D., from the VTT Technical Research Centre of Finland Ltd (“VTT”) at the PEGS conference in Lisbon, Portugal on Thursday, November 21, 2019. The scientific results are outlined in the presentation entitled ''Novel Highly Productive Production System for Biotherapeutics: Filamentous Fungus Myceliophthora thermophila''.

Item 9.01 Financial Statements and Exhibits |  |
(d) Exhibits |  |
The following exhibit is being furnished herein: |  |
Exhibit Number |  | Description
99.1 |  | Press Release dated as of November 25, 2019.
99.2 |  | VTT presentation entitled ''Novel Highly Productive Production System for Biotherapeutics: Filamentous Fungus Myceliophthora thermophila''

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 25, 2019

Dyadic International, Inc. |
By: | /s/ Mark A. Emalfarb
Name: | Mark A. Emalfarb
Title: | Chief Executive Officer